Using BM of patients with ischemic cardiomyopathy as starting material, we have here developed a standardized final GMP-compliant clinical-grade manufacturing protocol for human CD133+ cells fulfilling clinical-grade ATMP standards (ATMP-CD133). The gene discussed is PROM1; the disease is ischemic cardiomyopathy.